1155419-89-8 Usage
Description
BI-224436 is a chemical compound belonging to the benzofuran oxazole family, functioning as a non-nucleoside reverse transcriptase inhibitor (NNRTI). It exhibits potent activity against both wild-type HIV-1 and strains with resistance mutations, demonstrating its potential as a promising therapeutic agent for HIV-1 infection treatment.
Uses
Used in Pharmaceutical Industry:
BI-224436 is used as an antiviral agent for the treatment of HIV-1 infection. It inhibits the enzyme HIV-1 reverse transcriptase, thereby preventing the replication of the virus in host cells. Its activity against both wild-type and resistant strains makes it a valuable addition to the current arsenal of antiretroviral drugs.
BI-224436 is used as a component in combination therapies for HIV-1 infection. Its potent activity and low potential for drug-drug interactions make it suitable for use alongside other antiretroviral medications to enhance treatment efficacy and manage drug resistance.
Used in Preclinical Research:
BI-224436 is used as a research tool in preclinical studies to evaluate its pharmacokinetic properties, oral bioavailability, and potential for drug-drug interactions. These studies provide valuable insights into the compound's safety, efficacy, and suitability for further development as a standalone or combination therapy for HIV-1 treatment.
Check Digit Verification of cas no
The CAS Registry Mumber 1155419-89-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,5,5,4,1 and 9 respectively; the second part has 2 digits, 8 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1155419-89:
(9*1)+(8*1)+(7*5)+(6*5)+(5*4)+(4*1)+(3*9)+(2*8)+(1*9)=158
158 % 10 = 8
So 1155419-89-8 is a valid CAS Registry Number.
1155419-89-8Relevant articles and documents
Concise and Practical Asymmetric Synthesis of a Challenging Atropisomeric HIV Integrase Inhibitor
Fandrick, Keith R.,Li, Wenjie,Zhang, Yongda,Tang, Wenjun,Gao, Joe,Rodriguez, Sonia,Patel, Nitinchandra D.,Reeves, Diana C.,Wu, Jiang-Ping,Sanyal, Sanjit,Gonnella, Nina,Qu, Bo,Haddad, Nizar,Lorenz, Jon C.,Sidhu, Kanwar,Wang, June,Ma, Shengli,Grinberg, Nelu,Lee, Heewon,Tsantrizos, Youla,Poupart, Marc-André,Busacca, Carl A.,Yee, Nathan K.,Lu, Bruce Z.,Senanayake, Chris H.
, p. 7144 - 7148 (2015/06/16)
Abstract A practical and efficient synthesis of a complex chiral atropisomeric HIV integrase inhibitor has been accomplished. The combination of a copper-catalyzed acylation along with the implementation of the BI-DIME ligands for a ligand-controlled Suzuki cross-coupling and an unprecedented bis(trifluoromethane)sulfonamide-catalyzed tert-butylation renders the synthesis of this complex molecule robust, safe, and economical. Furthermore, the overall synthesis was conducted in an asymmetric and diastereoselective fashion with respect to the imbedded atropisomer. Atropselective: An efficient asymmetric synthesis of an atropisomeric HIV inhibitor has been accomplished. The combination of a copper-catalyzed acylation with the implementation of BI-DIME ligands for a ligand-controlled Suzuki cross-coupling and an unprecedented bis(trifluoromethane)sulfonamide-catalyzed tert-butylation renders the synthesis of this complex molecule robust, safe, and economical.
